Merck needs Killer B
Caspofungin (INN) (brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co.
Fungal infections cause more than 1.5 million deaths a year. Due to emerging antifungal drug resistance, novel strategies are urgently needed to combat life threatening fungal diseases.
Here, we identified the host defense peptide mimetic, brilacidin (BRI) as a synergizer with caspofungin (CAS) against CAS sensitive and CAS-resistant isolates of Aspergillus fumigatus, Candida albicans, C. auris, and CAS-intrinsically resistant Cryptococcus neoformans.
BRI combined with CAS significantly clears A. fumigatus lung infection in an immunosuppressed murine model of invasive pulmonary aspergillosis.
Our results indicate that combinations of BRI and antifungal drugs in clinical use are likely to improve the treatment outcome of aspergillosis and other fungal infections.
https://static1.squarespace.com/static/571535...3.8.23.pdf
Caspofungin (INN) (brand name Cancidas) is a lipopeptide antifungal drug from Merck & Co.
Fungal infections cause more than 1.5 million deaths a year. Due to emerging antifungal drug resistance, novel strategies are urgently needed to combat life threatening fungal diseases.
Here, we identified the host defense peptide mimetic, brilacidin (BRI) as a synergizer with caspofungin (CAS) against CAS sensitive and CAS-resistant isolates of Aspergillus fumigatus, Candida albicans, C. auris, and CAS-intrinsically resistant Cryptococcus neoformans.
BRI combined with CAS significantly clears A. fumigatus lung infection in an immunosuppressed murine model of invasive pulmonary aspergillosis.
Our results indicate that combinations of BRI and antifungal drugs in clinical use are likely to improve the treatment outcome of aspergillosis and other fungal infections.
https://static1.squarespace.com/static/571535...3.8.23.pdf
5
1